GleamWall
中文EN

DXCM DEXCOM INC

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1093557 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.0%
TTM net income YoY37.5%
TTM EPS YoY41.1%
Revenue 3-yr CAGR14.5%
Net income 3-yr CAGR38.0%

Margins

Gross margin63.4%
Operating margin24.0%
Net margin19.4%
FCF margin21.5%
EBITDA margin29.4%

Returns

ROE37.7%
ROA14.4%
ROIC (approx.)78.0%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets59.4%
Debt / equity0.00x
Current ratio1.74x
Interest coverage91.33x

Cash quality & payout

Operating cash flow / net income1.43x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue6.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.34B$1.31B$1.19B$1.26B$1.21B$1.16B$1.04B$1.11B
Cost of revenue$480.10M$478.40M$441.60M$466.90M$477.90M$468.30M$447.00M$457.70M
Gross profit$864.40M$830.00M$750.30M$792.70M$731.40M$688.80M$589.00M$655.80M
R&D expense$161.60M$153.00M$145.30M$148.20M$157.50M$148.20M$145.20M$139.50M
SG&A expense$375.60M$358.70M$349.70M$321.50M$331.40M$328.00M$310.10M$327.40M
Operating income$327.20M$318.30M$255.30M$323.00M$242.50M$212.60M$133.70M$188.90M
Interest expense$3.10M$3.00M$3.10M$4.20M$4.70M$4.70M$4.70M$4.90M
Pretax income$334.70M$317.50M$269.50M$340.70M$352.30M$241.10M$154.30M$211.30M
Income tax$59.60M$68.40M$70.00M$73.40M$68.50M$61.30M$48.90M$59.60M
Net income$275.10M$249.10M$199.50M$267.30M$283.80M$179.80M$105.40M$151.70M
EBITDA$401.70M$386.50M$322.40M$388.20M$306.10M$275.60M$193.70M$246.70M
EPS (basic)0.730.650.52—0.730.460.27—
EPS (diluted)0.720.640.51—0.700.450.27—
Weighted avg. shares (diluted)383.50M390.10M393.60M—407.40M408.20M407.50M—
Balance sheet
Cash & equivalents$961.40M$1.10B$1.12B$917.70M$1.84B$1.16B$904.90M$607.30M
Short-term investments——————$1.56B$1.73B
Receivables$1.19B$1.26B$1.09B$1.22B$1.11B$1.35B$1.16B$1.01B
Inventory$770.70M$726.40M$693.60M$629.10M$604.10M$570.70M$538.20M$542.60M
Current assets$3.92B$4.09B$4.33B$4.03B$5.22B$5.03B$4.55B$4.30B
PP&E, net$1.54B$1.58B$1.56B$1.56B$1.47B$1.46B$1.36B$1.34B
Goodwill$24.00M$24.10M$24.20M$24.20M$24.10M$24.10M$23.10M$22.80M
Intangibles$89.40M$101.60M$62.60M$70.80M$79.00M$87.20M$95.20M$103.40M
Total assets$6.24B$6.46B$6.63B$6.34B$7.50B$7.33B$6.75B$6.48B
Current liabilities$2.25B$2.36B$2.22B$2.14B$3.34B$3.31B$3.04B$2.93B
Total liabilities$3.70B$3.83B$3.68B$3.59B$4.77B$4.75B$4.49B$4.38B
Shareholders' equity$2.54B$2.62B$2.96B$2.75B$2.73B$2.57B$2.27B$2.10B
Shares outstanding373.00M377.40M385.90M384.80M390.00M392.20M392.10M390.70M
Cash flow statement
Operating cash flow$325.60M$269.20M$525.60M$294.00M$659.90M$303.00M$183.80M$301.40M
Capital expenditure$52.90M$84.70M$76.60M$101.90M$80.50M$94.10M$87.00M$124.60M
Free cash flow$272.70M$184.50M$449.00M$192.10M$579.40M$208.90M$96.80M$176.80M
Investing cash flow-$76.70M$329.80M-$298.50M$306.60M$192.80M-$63.60M$100.20M-$303.70M
Financing cash flow-$391.50M-$607.30M-$25.00M-$1.52B-$175.00M-$1.70M$12.50M-$1.60M
Depreciation & amortization$74.50M$68.20M$67.10M$65.20M$63.60M$63.00M$60.00M$57.80M
Stock-based compensation$36.80M$39.00M$43.30M$35.00M$45.10M$45.30M$34.20M$43.30M
Share buybacks$400.00M——$312.80M$187.20M——$0

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.